Accuracy of Determine TB-LAM Ag to detect TB in HIV infected patients associated with diagnostic methods used in Brazilian public health units

English version

Autoři: Aline Benjamin ^aff001; Solange Cesar Cavalcante ^aff001; Leda Fátima Jamal ^aff002; Denise Arakaki-Sanchez ^aff003; Josué Nazareno de Lima ^aff003; Jose Henrique Pilotto ^aff004; Francisco Ivanildo de Oliveira Junior ^aff006; Tâmara Newman Lobato Souza ^aff006; Maria Cristina Lourenço ^aff007; Maeve Brito de Mello ^aff008; Pedro Emmanuel Alvarenga Americano do Brasil ^aff009; Draurio Barreira ^aff010; Valeria Rolla ^aff001
Působiště autorů: Clinical Reasearch Laboratory on Mycobacteria, National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil ^aff001; STD/AIDS Reference and Training Center, Health Secretariat of State of São Paulo, Brazil ^aff002; National Tuberculosis Program, Ministry of Health, Brasilia, Brazil ^aff003; STD/AIDS Service, Nova Iguaçu General Hospital, Rio de Janeiro, Brazil ^aff004; Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil ^aff005; Institute of Infectious Disease Emilio Ribas, São Paulo, Brazil ^aff006; Bacteriology and Bioassay Laboratory, National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil ^aff007; Pan American Health Organization, Washington DC, United States of America ^aff008; Clinical Research Laboratory on Immunization and Surveillance in Health, National Institute of Infectious Diseases Evandro Chagas, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil ^aff009; Unitaid, Geneva, Switzerland ^aff010
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0221038

Souhrn

Background

Determine TB-LAM Ag (LAM) is a point of care test developed to diagnose tuberculosis (TB). The aim of this study was to evaluate the diagnostic performance of LAM in people living with HIV using Brazilian public health network algorithm for TB diagnosis.

Methods and findings

A cross-sectional study design was used to enroll 199 adult patients in two sites in Rio de Janeiro and two in São Paulo. The study enrolled HIV-infected patients with CD4 counts ≤200 cells/mm³ (in the Alere PIMA CD4 assay at study screening), patients coughing for at least 2 weeks or presenting a chest radiography suggestive of TB. LAM, in conjunction with sputum smear microscopy or Xpert MTB/RIF (Xpert) as compared to Mycobacterium tuberculosis culture, which was used as a reference standard. TB prevalence was 24.6%. Overall accuracy of LAM was 79.9% (73.8%-84.9%), positive and negative predictive values were 62.2% (46.1%-75.9%) and 84% (77.5%-88.8%), respectively. The overall LAM sensitivity was 46.9% (33.7%-60.6%) and specificity was 90.7% (84.9%-94.4%). The best performance of LAM was observed among patients with CD4 counts ≤50 cells/mm³ (sensitivity = 70.4% and specificity = 85.9%). When 2 respiratory smears were used in conjunction with LAM, sensitivity increased 22%, as compared to just 2 smears. Furthermore, LAM when used in conjunction with two respiratory smears, was as sensitive as compared to a single one. However, no improvement in TB diagnosis occurred when LAM was used with Xpert as compared to Xpert alone. Among 14 LAM false positive tests, Non-Tuberculosis Mycobacteria were isolated in three cases.

Conclusion

LAM is a point of care test that increased TB diagnosis in immunosuppressed HIV-infected patients when used in conjunction with smear microscopy, but not when used with Xpert in Brazilian public health network sites. Use of LAM test should be considered in settings where immunosuppressed HIV patients need rapid TB diagnosis.

Klíčová slova:

Diagnostic medicine – Tuberculosis – Tuberculosis diagnosis and management – Public and occupational health – HIV diagnosis and management – Brazil – Urine

Zdroje

1. N’Dhatz M, Domoua K, Coulibaly G, Traore F, Kanga K, Konan JB, et al. [Aspects of thoracic radiography of patients with tuberculosis and HIV infection in Ivory Coast]. Rev Pneumol Clin. 1994;50: 317–322. 7701211

2. Murray JF. Pulmonary complications of HIV-1 infection among adults living in sub-Saharan Africa [State of the Art Series. HIV infection in low-income, high-burden settings, Edited by Murray JF. Number 4 in the series]. The International Journal of Tuberculosis and Lung Disease. 2005;9: 826–835. 16104626

3. Elliott AM, Namaambo K, Allen BW, Luo N, Hayes RJ, Pobee JO, et al. Negative sputum smear results in HIV-positive patients with pulmonary tuberculosis in Lusaka, Zambia. Tuber Lung Dis. 1993;74: 191–194. doi: 10.1016/0962-8479(93)90010-U 8369514

4. Johnson JL, Vjecha MJ, Okwera A, Hatanga E, Byekwaso F, Wolski K, et al. Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration. Int J Tuberc Lung Dis. 1998;2: 397–404. 9613636

5. Ministério da Saúde. Manual de recomendações para o controle da tuberculose no Brasil. Brasília/DF: Ministério da Saúde: Secretaria de Vigilância em Saúde: Departamento de Vigilância Epidemiológica; 2011.

6. Ministério da Saúde. Recomendações sobre o diagnóstico da tuberculose por meio do teste rápido molecular para tuberculose. Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância Epidemiológica; 2014.

7. Flores LL, Steingart KR, Dendukuri N, Schiller I, Minion J, Pai M, et al. Systematic Review and Meta-Analysis of Antigen Detection Tests for the Diagnosis of Tuberculosis. Clinical and Vaccine Immunology. 2011;18: 1616–1627. doi: 10.1128/CVI.05205-11 21832100

8. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. European Respiratory Journal. 2011;38: 1398–1405. doi: 10.1183/09031936.00025711 21700601

9. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. The Lancet infectious diseases. 2012;12: 201–209. doi: 10.1016/S1473-3099(11)70251-1 22015305

10. World Health Organization P. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. [Internet]. Geneva, Switzerland; 2015. Available: http://www.who.int/entity/tb/areas-of-work/laboratory/policy_statement_lam_web.pdf?ua=1

11. Ministério da Saúde. Manual nacional de vigilância laboratorial da tuberculose e outras micobactérias. Brasília: Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância Epidemiológica; 2008.

12. Balcha TT, Winqvist N, Sturegård E, Skogmar S, Reepalu A, Jemal ZH, et al. Detection of lipoarabinomannan in urine for identification of active tuberculosis among HIV-positive adults in Ethiopian health centres. Trop Med Int Health. 2014;19: 734–742. doi: 10.1111/tmi.12308 24684481

13. Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients. Eur Respir J. 2012;40: 1211–1220. doi: 10.1183/09031936.00201711 22362849

14. Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, et al. Clinic-Based Urinary Lipoarabinomannan as a Biomarker of Clinical Disease Severity and Mortality Among Antiretroviral Therapy-Naive Human Immunodeficiency Virus-Infected Adults in South Africa. Open Forum Infect Dis. 2017;4. doi: 10.1093/ofid/ofx167 28979922

15. World Health Organization. Global tuberculosis report 2018. Geneva, Switzerland; 2018.

16. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine. 2010;363: 1005–1015. doi: 10.1056/NEJMoa0907847 20825313

17. Ministério da Saúde. Rede de Teste Rápido para Tuberculose no Brasil: primeiro ano da implantação. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis; 2015.

18. Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet. 2016;387: 1187–1197. doi: 10.1016/S0140-6736(15)01092-2 26970721

19. Gupta-Wright A, Corbett EL, van Oosterhout JJ, Wilson D, Grint D, Alufandika-Moyo M, et al. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial. The Lancet. 2018;392: 292–301.

20. Ferreira Medeiros M, Jardim MR, Vital RT, Nery JA da C, Sales AM, de Moraes MO, et al. An Attempt to Improve Pure Neural Leprosy Diagnosis Using Immunohistochemistry Tests in Peripheral Nerve Biopsy Specimens: Applied Immunohistochemistry & Molecular Morphology. 2014;22: 222–230. doi: 10.1097/PAI.0b013e31828dc70c 23702646

21. Nahas AA, Lima MI de S, Goulart IMB, Goulart LR. Anti-Lipoarabinomannan-Specific Salivary IgA as Prognostic Marker for Leprosy Reactions in Patients and Cellular Immunity in Contacts. Frontiers in Immunology. 2018;9. doi: 10.3389/fimmu.2018.01205